| Autor: |
Panchenko AV; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Fedoros EI; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia.; 2 Nobel Ltd, Saint Petersburg, Russia., Pigarev SE; 2 Nobel Ltd, Saint Petersburg, Russia., Maydin MA; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Gubareva EA; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Kireeva GS; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Tyndyk ML; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Kuznetsova AI; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Nekhaeva TL; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Danilova AB; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Baldueva IA; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia., Anisimov VN; 1 N.N. Petrov National Medical Research Center of Oncology, Saint Petersburg, Russia. |
| Abstrakt: |
This study aimed to evaluate the effect of lignin-derived polyphenolic composition BP-C3 on the efficacy and hematological toxicity of cyclophosphamide (CPA). Male and female Swiss-H derived mice bearing benzo[a]pyrene-induced soft tissue sarcomas were treated with CPA 300 mg/kg, BP-C3 75 mg/kg, or a combination. Tumor growth inhibition in male mice treated with CPA, BP-C3, or a combination of CPA and BP-C3 was significant and corresponded to 78%, 45%, and 82%, respectively, on day 21 after CPA administration on day 0. In female mice, tumor growth inhibition was 58%, -11%, and 35% when treated with CPA, BP-C3, or a combination of CPA and BP-C3, respectively. CPA administration resulted in significant hematological toxicity evidenced by a decreased white blood cell count on day 4 (2.43 ± 1.77 × 10 9 /L in male mice and 1.19 ± 0.71 × 10 9 /L in female mice) and anemia development on day 7 (6.55 ± 1.74 × 10 12 /L in male mice and 5.89 ± 2.24 × 10 12 /L in female mice). The red blood cell count measured on day 7 in animals treated with the combination of BP-C3 and CPA constituted 7.12 ± 1.17 × 10 12 /L and 7.36 ± 2.07 × 10 12 /L for male and female mice, respectively. The results of our study demonstrate the antitumor activity of BP-C3 in male mice bearing soft tissue sarcomas. Neither the antitumor activity nor the hematological toxicity of CPA were significantly influenced by BP-C3. A less pronounced effect of CPA on RBC count is demonstrated when this agent is given jointly with BP-C3. |
